Clinical Trials Logo

Depressive Disorder clinical trials

View clinical trials related to Depressive Disorder.

Filter by:

NCT ID: NCT02583867 Completed - Depression Clinical Trials

Predictors of Depression Treatment Response to Exercise

Start date: December 2015
Phase: Phase 3
Study type: Interventional

50 subjects with Major Depressive Disorder who are not currently receiving treatment will be enrolled in a 12-week exercise program, supervised by a trained exercise interventionist.

NCT ID: NCT02580656 Completed - Depression Clinical Trials

An Open Trial of Metacognitive Therapy for Anxiety and Depression in Cancer

Start date: January 2016
Phase: N/A
Study type: Interventional

Survival rates in cancer continue to improve, with over 2 million adult cancer survivors in the United Kingdom, projected to increase to 4 million by 2030. Around 25% of these survivors require treatment for clinical levels of emotional distress. The investigators will conduct a phase I open trial to test the potential efficacy of MCT in cancer survivors.

NCT ID: NCT02579928 Completed - Clinical trials for Major Depressive Disorder

Ketamine Infusion for Adolescent Depression and Anxiety

Start date: October 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the tolerability and short-term efficacy of a single ketamine infusion for the treatment of adolescents with 1) medication-refractory major depressive disorder (MDD) and/or 2) medication-refractory anxiety disorders (social anxiety disorder, panic disorder, generalized anxiety disorder and/or separation anxiety disorder).

NCT ID: NCT02579642 Completed - Depressive Disorder Clinical Trials

Effects of Low-dose Ketamine as an Adjunct to Propofol-based Anesthesia for Electroconvulsive Therapy

Start date: October 2015
Phase: Phase 4
Study type: Interventional

Ketamine has been used successfully as the sole medication for anesthesia in the setting of electroconvulsive therapy (ECT), and has more recently been studied as an adjunct agent in combination with propofol (the most commonly used anesthetic agent) to induce anesthesia for ECT. New literature postulates an anti-depressant effect of ketamine, which in ECT specifically may be helpful with regards to the overall goals of therapy (i.e. ECT indicated for severe or treatment-resistant depression). Current research focusing on ketamine with respect to its anti-depressant effect suggests it may even represent an alternative to ECT. This study will seek to determine whether ketamine when used in low-doses as an adjunct to propofol-based anesthesia for ECT has anti-depressant effects and whether it influences the characteristics of recovery from anesthesia in the ECT setting (i.e. vital sign parameters such as blood pressure and heart rate, quality of recovery, etc.).

NCT ID: NCT02579343 Completed - Clinical trials for Major Depressive Disorder

Adjunctive Treatment of Major Depression Utilizing Auricular Acupuncture

Start date: August 2015
Phase: N/A
Study type: Interventional

This will be a randomized, single blind study of 6 weeks duration involving the use of auricular acupuncture or sham acupuncture in the adjunctive treatment of depression in college students.

NCT ID: NCT02577250 Completed - Clinical trials for Stress Disorders, Post-Traumatic

Ketamine Infusions for PTSD and Treatment-Resistant Depression

Start date: May 2015
Phase: Phase 1
Study type: Interventional

The relationship between depression and trauma is well established. Co-occuring depression and post-traumatic stress disorder (PTSD) are associated with more severe symptoms and lower levels of functioning. Veterans with both depression and PTSD have been shown to be at much higher risk of suicide than individuals with only one of these disorders. Ketamine has been shown to have rapid antidepressant effects and also therapeutic action over PTSD symptoms. The purpose of this study is to see whether ketamine, when given as repeated infusions, can produce quick and sustained improvement in depression and PTSD symptoms for individuals who have not had their symptoms effectively treated by current treatments.

NCT ID: NCT02568865 Completed - Depression Clinical Trials

Noninvasive Physiologic Sensors to Assess Depression

Start date: January 15, 2016
Phase:
Study type: Observational

This project aims to use sensors to monitor physiological signals, sleep patterns, vocal characteristics, activity, location and phone usage in study patients with depression who are receiving standard treatment (compared with healthy controls).

NCT ID: NCT02567110 Completed - Depression Clinical Trials

Magnetic Resonance Spectroscopy (MRS) in Midlife Depression

Start date: July 2016
Phase:
Study type: Observational

The purpose of this study is to determine the impact of inflammation on central nervous system (CNS) glutamate, white matter pathology and alterations in behavior and cognition in middle-aged patients with major depression. Depression is associated with significant alterations in glutamate concentrations and white matter integrity, which has been associated with decreased antidepressant response, poor functional outcome, and cognitive impairment.

NCT ID: NCT02566980 Completed - Mood Disorders Clinical Trials

Biological Triggers of Depression in Pregnancy

Start date: October 23, 2014
Phase:
Study type: Observational

The goal of the study is to define and measure biological processes that contribute to the underlying pathophysiologic process of peri-partum depression to be used for identifying those at risk for developing it. This knowledge may also generate novel drug targets for peripartum depression that may be applicable to other types of depression.

NCT ID: NCT02565316 Completed - Depression Clinical Trials

Efficacy of Nepeta Menthoides Extract on Anxiety of Patients With Depression: a Double-blind Randomized Controlled Clinical Trial

Start date: November 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this study is to assess the efficacy of Nepeta menthoides as an anti anxiety herbal remedy for depressed patients , in a 6 week randomized double-blind controlled trial. A total of 70 adult outpatients between 18-65 ages referring to psychiatry clinic of Shiraz medical university, who having depression according to Persian‐language version of the Beck Depression Inventory‐Second edition and get score above 11 according to Persian version of Beck Anxiety Inventory (BAI) and diagnosis is confirmed by at two psychiatrists are randomly allocated into two groups and assign to receive 400 mg of freeze dried powder of Nepeta menthoides or 50 mg of sertraline in the uniformed capsules twice daily (in the morning and 1-2 hours before sleeping time at night). Exclusion criteria were pregnancy and lactation, allergy to N. menthoides and Lamiaceae family, patients with suicidal thoughts or previous suicidal attempt, patients with unstable cardiac, renal and hepatic diseases, seizure and hypothyroidism and patients who used substances or alcohol and patients who had indication for electroconvulsive therapy.. Severity of anxiety (by Persian version of Beck Anxiety Inventory (BAI)) and also common possible side effects of drugs will assess in baseline, 2nd week, 4th week and then two weeks after the end of the intervention (in 6th week)